ARIAD Pharmaceuticals Inc (ARIA)

10.02
0.58 5.50
NASDAQ : Health Care
Prev Close 10.60
Open 10.54
Day Low/High 9.95 / 10.85
52 Wk Low/High 4.37 / 10.83
Volume 7.86M
Avg Volume 5.07M
Exchange NASDAQ
Shares Outstanding 192.71M
Market Cap 2.04B
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ARIAD (ARIA) Stock Pops After Q2 Beat

ARIAD (ARIA) Stock Pops After Q2 Beat

ARIAD (ARIA) stock is jumping in afternoon trading today after the company reported better-than-expected results for the second quarter before Thursday's market open.

ARIAD Reports Second Quarter And First Half 2016 Financial Results

ARIAD Reports Second Quarter And First Half 2016 Financial Results

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the second quarter and first half of 2016, including revenue from sales of Iclusig ® (ponatinib).

Insider Trading Alert - SKUL, EA And ARIA Traded By Insiders

Insider Trading Alert - SKUL, EA And ARIA Traded By Insiders

Stocks with insider trader activity include SKUL, EA and ARIA

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

Chipotle, Wendy's on the bull side and gold stocks on the bear side.

These 5 Stocks Under $10 Are Set to Soar Higher

These 5 Stocks Under $10 Are Set to Soar Higher

Here's a technical look at how to trade five stocks trading for less than $10 a share that are headed for breakouts.

Barbarian At The Gate: ARIAD Pharmaceuticals (ARIA)

Barbarian At The Gate: ARIAD Pharmaceuticals (ARIA)

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

ARIAD To Webcast Conference Call On Second Quarter 2016 Financial Results

ARIAD To Webcast Conference Call On Second Quarter 2016 Financial Results

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its second quarter 2016 financial results on Thursday, July 28, 2016, before the market opens.

ARIAD Announces Webcast Of Its Annual Stockholders Meeting

ARIAD Announces Webcast Of Its Annual Stockholders Meeting

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its Annual Meeting of Stockholders will be webcast live on July 21, 2016 and can be accessed by visiting the investor relations section of the Company's...

ARIAD Pharmaceuticals (ARIA) Marked As A Dead Cat Bounce Stock

ARIAD Pharmaceuticals (ARIA) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "dead cat bounce" (down big yesterday but up big today) candidate

ARIAD Completes Strategic Review And Announces Plans For Growth

ARIAD Completes Strategic Review And Announces Plans For Growth

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the completion of its strategic review and its plans for future growth and vision to become a leader in the discovery, development and commercialization of...

ARIAD Announces Distribution Agreements For Iclusig® In Latin America And The Middle East/North Africa

ARIAD Announces Distribution Agreements For Iclusig® In Latin America And The Middle East/North Africa

ARIAD Pharmaceuticals, Inc. (ARIAD; NASDAQ:ARIA) today announced that it has completed two distribution agreements for Iclusig ® (ponatinib) outside of the United States.

ARIAD Initiates Submission Of New Drug Application For Brigatinib To The U.S. Food And Drug Administration Ahead Of Plan

ARIAD Initiates Submission Of New Drug Application For Brigatinib To The U.S. Food And Drug Administration Ahead Of Plan

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the initiation of a New Drug Application (NDA) submission for its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to the U.

ARIAD Announces Long-Term Safety And Efficacy Data Of Ponatinib From Phase 2 Pace Clinical Trial

ARIAD Announces Long-Term Safety And Efficacy Data Of Ponatinib From Phase 2 Pace Clinical Trial

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced long-term follow-up data from its pivotal Phase 2 PACE clinical trial of Iclusig ® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated...

ARIAD To Host Analyst & Investor Day In New York City

ARIAD To Host Analyst & Investor Day In New York City

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will host an Analyst & Investor Day for its research analysts and institutional investors on Friday, June 17 at 8:30 a.

Today's Weak On High Volume Stock: ARIAD Pharmaceuticals (ARIA)

Today's Weak On High Volume Stock: ARIAD Pharmaceuticals (ARIA)

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a weak on high relative volume candidate

Cancer Drug Stocks: The Winners and Losers From ASCO 2016

Cancer Drug Stocks: The Winners and Losers From ASCO 2016

A summary (and somewhat subjective) breakdown of winners and losers from the American Society of Clinical Oncology annual meeting.

ARIAD's Investigational Medicine Brigatinib Demonstrates 54 Percent Confirmed Objective Response Rate And 12.9-Month Median Progression-Free Survival In ALTA Study

ARIAD's Investigational Medicine Brigatinib Demonstrates 54 Percent Confirmed Objective Response Rate And 12.9-Month Median Progression-Free Survival In ALTA Study

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical data on brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, from the pivotal ALTA trial in patients who had...

ARIAD Presents Data From Mutational Profiling In Crizotinib-Resistant Patients Treated With Investigational Medicine Brigatinib Showing Similar Response Rates In Patients With And Without Secondary ALK Mutations

ARIAD Presents Data From Mutational Profiling In Crizotinib-Resistant Patients Treated With Investigational Medicine Brigatinib Showing Similar Response Rates In Patients With And Without Secondary ALK Mutations

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced clinical data from an analysis aimed at characterizing the activity of its investigational tyrosine kinase inhibitor (TKI), brigatinib, in patients with...

ARIAD Presents Long-Term Phase 1/2 Trial Follow Up On Investigational Drug Brigatinib With Median Time On Treatment Of 17 Months In ALK+ NSCLC Patients

ARIAD Presents Long-Term Phase 1/2 Trial Follow Up On Investigational Drug Brigatinib With Median Time On Treatment Of 17 Months In ALK+ NSCLC Patients

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical data on its investigational tyrosine kinase inhibitor (TKI), brigatinib, in patients with anaplastic lymphoma kinase-positive (ALK+)...

Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's Post-Market Leader Stock

Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a post-market leader candidate

ARIAD Completes The Sale Of Its European Operations And Out-License Of European Rights To Iclusig®

ARIAD Completes The Sale Of Its European Operations And Out-License Of European Rights To Iclusig®

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it has completed the sale of its European operations to Incyte Corporation and entered into the previously announced license agreement for Incyte to...

ARIAD To Present At The Jefferies 2016 Global Healthcare Conference

ARIAD To Present At The Jefferies 2016 Global Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Jefferies 2016 Global Healthcare Conference being held in New York City.

Ariad Pharmaceuticals Is Nearly Done Building Base Pattern

We should go long ARIA on available weakness and risk below $6.50.

Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a strong on high relative volume candidate

ARIAD Announces Initiation Of Phase 1/2 Clinical Trial Of AP32788, An Investigational Oral Inhibitor Of EGFR And HER2, In Patients With Non-Small Cell Lung Cancer

ARIAD Announces Initiation Of Phase 1/2 Clinical Trial Of AP32788, An Investigational Oral Inhibitor Of EGFR And HER2, In Patients With Non-Small Cell Lung Cancer

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced initiation of the Phase 1/2 clinical trial of AP32788, an investigational tyrosine kinase inhibitor (TKI) designed as a targeted therapy for patients with...

Insider Trading Alert - DEPO, ARIA And ROG Traded By Insiders

Insider Trading Alert - DEPO, ARIA And ROG Traded By Insiders

Stocks with insider trader activity include DEPO, ARIA and ROG

ARIAD Announces Appointment Of Jennifer L. Herron As Chief Commercial Officer

ARIAD Announces Appointment Of Jennifer L. Herron As Chief Commercial Officer

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Jennifer L.

ARIAD Announces Pricing And Reimbursement For Iclusig In France

ARIAD Announces Pricing And Reimbursement For Iclusig In France

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that negotiations with the Economic Committee on Health Care Products in France regarding pricing and reimbursement for Iclusig ® (ponatinib) have now...